Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ganglioneuroblastoma × dinutuximab × Clear all

Phase

Phase 2 3 Phase 3 2 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 4 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Osteosarcoma 1 Medulloblastoma 1 Glioma 1 Glioblastoma 1 Ganglioneuroblastoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1

Interventions

sargramostim 1 iberdomide 1 dinutuximab 1 Topotecan 1 Magnetic Resonance Spectroscopy 1 Cyclophosphamide 1 Colony-Stimulating Factors 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07437963 2026-03-19

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡